This model integrates clinical parameters (such as joint involvement, symptom duration, morning stiffness), serological markers (ACPA, RF) and acute phase reactants to generate a weighted score corresponding to the probability of developing RA within 1 year. Here, PRTN3 is linked to rheumatoid arthritis.